BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

This study is testing a CAR T-cell therapy called BCMA-CD19 cCAR for patients with multiple myeloma or a related blood cancer called plasmacytoid lymphoma. CAR T-cell therapy takes a patient's immune cells, engineers them in the lab to recognize and attack cancer cells, and infuses them back. This particular therapy targets two proteins — BCMA and CD19 — that appear on cancer cells. **You may be eligible if...** - You have multiple myeloma or plasmacytoid lymphoma - You have exhausted standard treatment options - You have stopped immunosuppressive drugs or steroids for at least 1 week - You are not pregnant - You have signed an informed consent form **You may NOT be eligible if...** - You have had a prior solid organ transplant - A potentially curative treatment (like chemotherapy or stem cell transplant) is still available to you - You have previously received a treatment targeting both BCMA and CD19 together Talk to your doctor to see if this trial is right for you.